The AAN/AHS guidelines found moderate evidence of effectiveness for riboflavin (vitamin B2), magnesium, and feverfew. A 3-month, randomized, controlled trial of high-dose riboflavin (400 mg) found that riboflavin was superior to placebo in reducing attack frequency and headache days.
Although SSRIs are widely used, data regarding their efficacy in migraine prevention are lacking; consequently, SSRIs are not recommended for migraine prevention. Tonabersat is a novel benzopyran compound that markedly reduces cortical spreading depression (CSD) and CSD-associated events by inhibiting gap-junction communication between neurons and satellite glial cells in the trigeminal ganglion. In a randomized, double-blind, placebo-controlled crossover trial, preventive therapy with tonabersat reduced the frequency of aura attacks with or without headache but had no efficacy on non-aura attacks.
The pipeline of future compounds for the treatment of acute migraine headaches also includes the following medications:
Transient receptor potential vanilloid type 1 antagonists
Prostaglandin E receptor 4 receptor antagonists
Serotonin 5HT1(F) receptor agonists
Nitric oxide synthase inhibitors
For more about the treatment of migraine, read here.
Related Resources
Medscape © 2015
WebMD, LLC
Cite this: Amy Kao, Sumaira Nabi, Jasvinder Chawla. Fast Five Quiz: How Much Do You Know About Migraines? - Medscape - May 14, 2015.
Comments